fatty acid synthase; SC, synthetic complete; VLCFA, very long-chain fatty acid.
Introduction
Arrhythmogenic right ventricular dysplasia (ARVD) is an inherited heart disease characterized by a gradual loss of right ventricular myocardium and fibro-fatty infiltration with a prevalence of 1 in 2,500 to 1 in 5,000 (1, 2) . It is a major cause of sudden death in young people and athletes (1, 2) . To date, eight genes have been identified as being associated with ARVD: the DSP gene encoding desmoplaskin, PKP2 encoding plakophilin 2, DSC2 encoding desmocollin 2, DSG2 encoding desmoglein 2, JUP encoding plakoglobin, TGFB3 encoding transforming growth factor β3, TMEM43 encoding transmembrane protein 43, and TP63 encoding tumor protein 63 (3) . Most of these ARVD-causing mutations are autosomal dominant, although some autosomal recessive mutations have also been identified (2) . Five of the ARVD genes encode desmosomal proteins (desmoplaskin, plakophilin 2, desmocollin 2, desmoglein 2, and plakoglobin) (1) (2) (3) . Desmosome functions in cell adhesion, transcription regulation of genes involved in adipogenesis and apoptosis, regulation of gap junctions, and calcium homeostasis (2) . The ARVD mutations demonstrate incomplete penetrance and variable expressivity (1, 2) , suggesting that environmental factors and differences in genetic background are also involved in the pathogenesis.
Several linkage analyses have identified ARVD-associated loci differing from the above genes (2) . One such locus was mapped at 10p12-14 with ARVD segregating as an autosomal, dominant transmission (4) . The HACD1 (PTPLA) gene is located in this region, and a point mutation known to cause a K64Q substitution in the HACD1 protein was found in all the affected individuals of a large ARVD family (n=10) (5) . However, this mutation was also detected in normal control subjects (3 alleles per 100 chromosomes) (5) . Incomplete penetrance of ARVD has impeded conclusions as to whether this mutation causes ARVD, making the enzymatic characterization of HACD1 (K64Q) essential for the determination. Until recently, however, even the function of HACD1 had not been 4 known. In 2008, though, we identified HACD1 as the 3-hydroxyacyl-CoA dehydratase involved in elongation of very long-chain fatty acids (VLCFAs) (6) . This work enabled us to perform biochemical analyses of an HACD1 (K64Q) mutant protein.
VLCFAs are fatty acids with a chain-length of ≥20 that function in numerous cellular processes, including sphingolipid biogenesis, inflammation, immunity, fetal growth and development, retinal function, and brain development (7) (8) (9) . VLCFA elongation occurs by cycling through a 4 step process (condensation, reduction, dehydration, and reduction), with 2 carbons added through each cycle. The first condensation step is catalyzed by one of seven elongases (ELOVL1-7) (8, 9) . The second and fourth reduction steps are catalyzed by the reductases KAR and TER, respectively (10).
HACD1/PTPLA and three homologous proteins (HACD2/PTPLB, HACD3/PTPLAd1, and HACD4/PTPLAd2) are responsible for the third step, catalyzing the dehydration of 3-hydroxyacyl-CoA (6) . HACD1 mRNA is expressed in heart at high levels and is also found in skeletal muscle, but virtually no expression has been detected in other tissues tested (5) . The high level expression of HACD1 mRNA in heart is in strong accordance with the concept that HACD1 is ARVD-causative gene.
In the presented study we performed an enzymatic characterization of the mutant HACD1 (K64Q). HACD1 (K64Q) exhibited 3-hydroxyacyl-CoA dehydratase activity at levels indistinguishable from wild type HACD1. In addition, ectopic expression of HACD1 (K64Q) was able to restore the growth of a yeast mutant defective in 3-hydroxyacyl-CoA dehydratase (Phs1).
Moreover, HACD1 (K64Q) localized normally in the ER and interacted with other components of the VLCFA elongation machinery. Finally, we could not find any dominant negative effects of HACD1 (K64Q) on VLCFA elongation when overproduced in HEK 293T cells or in C2C12 myoblasts. All these results suggest that the HACD1 (K64Q) mutation is not responsible for ARVD pathology.
Materials and Methods

Cell culture and transfection
HEK 293T and C2C12 cells were grown in Dulbecco's modified Eagle's medium (Sigma, St.
Louis, MO) containing 10% fetal bovine serum and supplemented with 100 units/ml penicillin and 100 µg/ml streptomycin. The C2C12 myoblasts were provided by the RIKEN BRC through the National Bio-Resource Project of the MEXT, Japan. HEK 293T cells were grown in 0.3% 
Plasmids
The pCE-puro 3xFLAG-1, pCE-puro HA-1, and the pCE-puro His 6 -Myc-1 plasmids are mammalian expression vectors and were designed to produce an N-terminal 3xFLAG-tagged protein, an N-terminal HA-tagged protein, and an N-terminal tandemly oriented His 6 and Myc epitope (His 6 -Myc)-tagged protein, respectively. The pCE-puro 3xFLAG-HACD1, pCE-puro His 6 -Myc-HACD1, and pCE-puro HA-ELOVLx (where x is each ELOVL number) plasmids have been described previously (6) . The pAKNF313 plasmid (HIS3 marker) is a yeast expression vector and was designed to produce an N-terminal 3xFLAG-tagged protein.
The KAR and TER genes were amplified from an EST clone (ID 3622879) (Open Biosystems, cloned into the pAKNF313 plasmid to generate the pKH10 and pKH11 plasmids, respectively.
Immunological Assays
Co-immunoprecipitation experiments were performed as described previously (12), using the anti-Myc antibody PL14 (Medical & Biological Laboratories, Nagoya, Japan). Immunoblotting was performed as described previously (13) using the anti-FLAG antibody M2 (1 µg/ml), the anti-HA antibody HA-7 (1:2000 dilution; Sigma), or the anti-Myc antibody PL14 (0.5 µg/ml) as the primary antibody and HRP-conjugated anti-mouse IgG F(ab') 2 fragment (from GE Healthcare Bio-Sciences, Piscataway, NJ, and diluted 1:7500) as the secondary antibody. Labeling was detected using ECL TM Reagents or an ECL plus System for Western Blotting Detection (both from GE Healthcare
Bio-Sciences). Microscopic immunofluorescence studies were performed with the anti-Myc antibody PL14 (5 µg/ml) and an anti-calreticulin antibody (5 µg/ml; Alexis, Lausen, Switzerland) (6).
In Vitro 3-Hydroxyacyl-CoA Dehydratase Assays
In vitro 3-hydroxyacyl-CoA dehydratase assays were performed as described previously (6) .
Using anti-FLAG M2 agarose (Sigma), 3xFLAG-tagged HACD1 proteins were purified from HEK 293T cells transfected with the pCE-puro 3xFLAG-HACD1 or pCE-puro 3xFLAG-HACD1 (K64Q)
plasmid. In vitro 3-hydroxyacyl-CoA dehydratase assays were performed by mixing purified proteins in reaction buffer (total volume of 40 µl; 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and 1X protease inhibitor mixture 
In Vitro Fatty Acid Elongation Assays
In vitro fatty acid elongation assays were performed essentially as described elsewhere (14) Lipids were saponified, acidified, extracted, and separated by normal phase TLC as described above.
Results
HACD1 (K64Q) exhibits normal 3-hydroxyacyl-CoA dehydratase activity
HACD1 was recently identified as a 3-hydroxyacyl-CoA dehydratase in mammals (6) . To examine and compare their enzyme activities, the mutant HACD1 (K64Q) and wild type HACD1
were expressed in HEK 293T cells as N-terminally 3xFLAG tagged proteins. The proteins were affinity-purified with anti-FLAG antibodies then subjected to an in vitro 3-hydroxyacyl-CoA dehydratase assay using [ 14 C]3-hydroxypalmitoyl-CoA as a substrate. The wild type 3xFLAG-HACD1 protein exhibited dehydratase activity in a time-dependent manner (Fig. 1A) .
Moreover, the 3xFLAG-HACD1 (K64Q) protein exhibited activity at levels similar to those of the wild type protein (Fig. 1A) .
HACD1 is conserved among eukaryotes, and yeast have an HACD1 homolog called Phs1 (15) .
Since the production of VLCFAs in yeast is essential for growth, deletion of the PHS1 gene is lethal (Fig. 1B) . This result confirms the conclusion drawn from the above result that HACD1 (K64Q) is an active enzyme.
HACD1 (K64Q) is localized in the ER
To fulfill its own function in vivo, each protein must be localized in the proper organelle. (16) . With this in mind, we next examined the possibility that the K64Q mutation affects the intracellular localization of HACD1 using C2C12 myoblasts. Lys-64 had been predicted to be a part of a nuclear localization signal, although the intracellular localization of wild type or the K64Q mutant was not investigated in that report (5) . In our studies here, indirect immunofluorescence microscopy demonstrated that the wild type His 6 -Myc tagged HACD1 protein was localized in the ER, as illustrated by the co-localization of the ER marker calreticulin (Fig. 2) . The HACD1 (K64Q) mutant was also localized in the ER and similarly merged with calreticulin ( Fig. 2) . Therefore, HACD1 is an ER-resident protein, and the K64Q mutation did not disturb its localization.
HACD1 (K64Q) interacts normally with other components of the VLCFA elongation machinery
In yeast, enzymes involved in the VLCFA elongation cycle form an elongase complex (15) . In our previous study we revealed that HACD1 interacts with the elongases involved in this complex (ELOVL1-7) (6). Here, we examined whether HACD1 also interacts with other components of the VLCFA elongation machinery, specifically the reductases KAR and TER, which are responsible for the second and fourth steps in the VLCFA elongation, respectively. We conducted co-immunoprecipitation experiments using anti-Myc antibodies and lysates prepared from HEK 293T cells expressing combinations of a His 6 -Myc -tagged wild type HACD1 and each FLAG-tagged reductase protein. We found that wild type HACD1 interacts with both KAR (Fig. 3A) and TER ( Fig.   3B ), indicating that mammalian proteins also form a VLCFA elongase complex.
As described above, HACD1 (K64Q) exhibited normal enzyme activity and localization.
However, it is possible that interaction with other components of the VLCFA elongase complex is impaired by the K64Q mutation, resulting in inefficient VLCFA production. Therefore, we investigated the interactions of HACD1 (K64Q) with the other components of the VLCFA elongase complex by co-immunoprecipitation experiments. Our results indicate that HACD1 (K64Q) interacts with each of the ELOVL elongases ELOVL1-7 (Fig. 3C) , and with KAR (Fig. 3A) or TER (Fig. 3B) , as efficiently as the wild type HACD1 protein. Thus, the K64Q mutation does not impair the formation of the elongase complex.
HACD1 (K64Q) does not exhibit any dominant negative effects on VLCFA elongation
The mutation in the 10p12-14 chromosomal locus associated with ARVD is segregated as an autosomal dominant transmission (4). Therefore, it was expected that if the K64Q mutation is ARVD-causative, expression of the HACD1 (K64Q) protein would exhibit a dominant negative effect on VLCFA elongation. To test this possibility, we performed an in vitro fatty acid elongation assay, in which total membrane fractions prepared from HEK 293T cells transfected with the vector or plasmid encoding wild type HACD1 or HACD1 (K64Q) were incubated with palmitoyl-CoA and (Fig. 4) . Overproduction of wild type HACD1 did not cause any significant change in the amounts of the acyl-CoA products, consistent with the theory that the step catalyzed by HACD1 is not rate-limiting (Fig. 4) . The expression of HACD1 (K64Q) also did not affect the product levels (Fig. 4) .
Similar results were obtained when C2C12 cells were used instead of HEK 293T cells (Fig. 4) . These results indicate that the HACD1 (K64Q) protein exhibits no dominant negative effect in regards to VLCFA elongation.
13
Discussion
ARVD is a hereditary cardiomyopathy characterized by replacement of myoblasts with fibrofatty tissue, ventricular tachyarrythmias, and sudden death (1, 2) . Although eight genes have been identified as ARVD-causative genes, including many that encode components of the cardiac desmosome, some ARVD-associated chromosomal loci have yet to be associated with their responsible genes (2, 3) . The HACD1 gene is located in one such locus, 10p12-14, and previous results had demonstrated that ARVD patients carry a point mutation that causes K64Q substitution in the HACD1 protein (5). However, this mutation was also found in normal controls at low frequency (5) . The incomplete penetrance nature of ARVD has made it difficult to interpret whether this mutation is responsible for the ARVD pathology. Therefore, enzymatic characterization of HACD1 (K64Q) was needed.
In the presented study, we examined the enzyme activity of HACD1 (K64Q) and found that it exhibited a 3-hydroxyacyl-CoA dehydratase activity comparable to that of the wild type HACD1 protein (Fig. 1A) . Expression of HACD1 (K64Q) in the TetO 7 -PHS1 cells restored their deficient growth (Fig. 1B) . Moreover, HACD1 (K64Q) was properly localized in the ER (Fig. 2) and was able to interact with other components of the VLCFA elongase complex, similar to wild type HACD1 (Fig.   3 ). All these results indicate that HACD1 (K64Q) exhibits enzymatic properties indistinguishable from wild type HACD1.
HACD1 is conserved among eukaryotes, and together the homologs constitute the Phs1 family.
We previously examined the membrane topology of the yeast Phs1 protein and determined it to be a six-span membrane protein with its N-terminus and C-terminus both facing toward the cytosol (11).
When amino acid sequences of 31 Phs1 family members from 24 organisms were compared, 22 amino acids were found to be conserved (11) . By mutating each of the 22, we determined that six 14 amino acids are important in Phs1 function, and, of these, two are indispensable (11) . The six important residues are each located within or near transmembrane regions 3 and 5 (11) . Lys-64 of HACD1 is located in the first N-terminal hydrophilic domain. This residue is not conserved among Phs1 family members. Furthermore, the lengths of the N-terminal hydrophilic domains vary among Phs1 family members, with the proteins found in lower eukaryotes having shorter N-terminal hydrophilic domains; these domains do not have the residue corresponding to Lys-64 of human HACD1. The low evolutionary conservativeness of this residue is consistent with our findings that Lys-64 of HACD1 was dispensable for HACD1 function.
The ARVD mutation associated with 10p12-14 segregates in an autosomal dominant fashion, as do most of the other ARVD mutations (4). Therefore, we investigated whether HACD1 (K64Q) exhibited any dominant negative effects on VLCFA elongation. However, no such effects were observed for HACD1 (K64Q) when overproduced in HEK 293T cells or C2C12 myoblasts (Fig. 4 ).
All these results strongly suggest that the HACD1 (K64Q) mutation is not responsible for the ARVD pathology.
The HACD1 gene may not be responsible for the ARVD pathology, but there could be others not yet recognized. One candidate gene is CACNB2, located at 10p12 near the HACD1 gene. The CACNB2 gene encodes the β 2b subunit of the L-type calcium channel. A recent study reported that a loss-of-function mutation in this gene is associated with a familial sudden cardiac death syndrome with ST-segment elevation and short QT intervals (17) . Although the electrocardiogram abnormalities associated with the reported ARVD mutation at 10p12-14 would seem not to correlate with the CACNB2-associated pathology, it is possible that mutational differences could cause such phenotypic
differences.
An insertion mutation in the HACD1 gene causes an autosomal recessive centronuclear 15 myopathy in dogs (18) . Although skeletal muscle atrophy is observed in this disease, abnormalities in heart have not been reported. HACD1 is highly expressed in heart, suggesting that it plays unknown functions in that organ.
We recently reported that HACD proteins interact with ELOVLs (6). In the presented study, we demonstrated that HACD1 also interacts with the reductases KAR and TER (Fig. 3) . Thus, all components of VLCFA elongation form an elongase complex. These interactions had already been established for the yeast VLCFA elongation components, so it would appear that the VLCFA elongase complexes are evolutionally conserved. Mammalian fatty acid synthase (FAS), which produces palmitic acid, is a multi-enzyme and incorporates all catalytic activities of its cyclic reaction as discrete domains on one polypeptide chain (19) . Like FAS, the adjacent positioning of the catalytic centers of the four elongation reactions of VLCFA elongation may contribute to efficient cycling.
However, future in vitro studies are needed for elucidation of the molecular mechanism of the presumptive cooperative progression in the VLCFA elongation cycle. (3xFLAG-HACD1), or pKH11 (3xFLAG-HACD1 (K64Q)) plasmid. Cells were grown for 2 days at 30
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